Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Sept 2021

Veit Guido, Vaccarin Christian, Lukacs Gergely L

Abstract excerpt

Trikafta, the combination of elexacaftor (VX-445), tezacaftor (VX-661) and ivacaftor (VX-770), was approved for therapy of cystic fibrosis (CF) patients with at least one allele of the CFTR mutation F508del. While the corrector function of VX-445 is well established, here we investigated the putative potentiator activity of VX-445 alone and in combination with VX-770. Acute addition of VX-445 increased the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cells, Cultured
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Nasal Mucosa

Share to Pyrazoles

Share to Pyridines

Share to Pyrrolidines

Source

Open in PubMed Open full text

Identifiers

PMID: 33775603
DOI: 10.1016/j.jcf.2021.03.011
PMCID: PMC8463622

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR.PMID 33775603Read ↗

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.Semantic proximity Read ↗

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two<i>F508del</i>allelesSemantic proximity Read ↗

Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators.Semantic proximity Read ↗

Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor.Semantic proximity Read ↗

The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.Semantic proximity Read ↗

Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.Semantic proximity Read ↗

Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.Semantic proximity Read ↗

CFTR Modulators: Current Status and Evolving Knowledge.Semantic proximity Read ↗

Mutation-specific downregulation of CFTR2 variants by gating potentiators.Semantic proximity Read ↗

CFTR correctors potentiate gating mutants causing cystic fibrosis.Semantic proximity Read ↗

VX-770-mediated potentiation of numerous human CFTR disease mutants is influenced by phosphorylation level.Semantic proximity Read ↗

Ivacaftor potentiation of multiple CFTR channels with gating mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.